Journal of Cell Science & Therapy

Journal of Cell Science & Therapy
Open Access

ISSN: 2157-7013

+44 1300 500008

Effect of metabolic surgery on non-alcoholic fatty liver disease


Joint Event on European Pathology and Infectious Disease Conference & International Epigenetics and Epitranscriptomics Conference

November 26-27, 2018 Helsinki, Finland

Royce P Vincent

Kings College Hospital NHS Foundation Trust, UK

Scientific Tracks Abstracts: J Cell Sci Ther

Abstract :

Non-Alcoholic Fatty Liver Disease (NAFLD) has become increasingly common worldwide over the last decades due to the obesity epidemic. By definition NAFLD requires that there is evidence of hepatic steatosis, either by imaging/histology or there are no causes for secondary hepatic fat accumulation-significant alcohol consumption, steatogenic medication, hereditary disorders etc. and is characterized by liver steatosis (accumulation of triglycerides >5% in liver weight). NAFLD is strongly associated with metabolic syndrome (insulin resistance, obesity and dyslipidemia). The disease reaches a peak in the fifth and sixth decades of life and at present nearly 25% of adults in Europe with fatty liver have NAFLD. NAFLD is a clinic-pathological entity that comprises a liver disease spectrum spanning from non-inflammatory isolated steatosis to Non- Alcoholic Steatohepatitis (NASH), a more aggressive form of the disease, which is characterized by steatosis, inflammatory changes and varying degrees of liver fibrosis to end-stage liver disease. Furthermore, NAFLD may be complicated by cirrhosis or Hepatocellular Carcinoma (HCC). It is now set to become the major cause of liver transplantation in adults as it is the most important cause of cryptogenic cirrhosis. The pathogenesis of NAFLD is multifactorial but is yet to be fully elucidated. This session will explore our current knowledge about the pathophysiology of obesity associated liver disease, its management strategies and the role of metabolic surgery to address this global health problem.

Biography :

Royce P Vincent is a Consultant Chemical Pathologist at King’s College Hospital NHS Foundation Trust and an Honorary Senior Lecturer at King’s College London, UK. He has a special interest in nutrition and endocrinology and is the Clinical Lead for Biochemistry and Parenteral Nutrition Services. He has obtained his MD (Res) at Imperial College London and his research interests are in obesity, endocrinology and clinical nutrition. He has published multiple original and review articles and is serving as an international Editorial Board Member for Translational Metabolic Syndrome Research.

E-mail: royce.vincent@nhs.net

 

Top